TY - JOUR T1 - Dynamics of MBT drug resistance in a specialized urban TB hospital (Saratov, Russia) JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P2685 AU - Liudmila Pankratova AU - Ekaterina Pereselentseva AU - Aleksandr Filippov Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P2685.abstract N2 - DR dynamics over 2006-2011 was studied in a Specialized Urban TB Hospital. Sputum from 1962 was tested for MBT DR. During the years 2006-2009, both primary (from 36.3% to 68.0%) and secondary DR (82.1% to 90.8%) was found to be increasing. But in 2011 primary DR decreased to 54.8% (a 13.2% drop). Secondary DR keeps growing: 88.7% in 2010 and 91.5% (the absolute peak over the entire study period) in 2011. Similar tendencies have been found for monoresistance.Over 2006-2009, MDR in primary DR doubled – from 16.8% to 34.2% (p<0,001), and in secondary DR it increased from 53.8% to 64.0% (2010). However, the latter parameter is showing signs of slight improvement: in 2011, MDR was 25.8% (8.4% less) for primary DR and 59.8% (-4.2%) for secondary DR.By specific drugs: primary DR to H decreased in 2009-2011 to 32.3% (-16.4%), to R to 29.0% (-7.8%), to E to 19.4% (-8.2%), to S to 28.7% (-19.2%). Regretfully, a similar tendency was not observed for seconday DR.Dynamics analysis of MBT resistance to various H concentrations during treatment of 44 patients showed that 11.4%% of them were and remained DR to H (10 mkg/ml) 59.1% of them remained non-DR to H (10 mkg/ml) 11.4% developed DR to this concentration during treatment, in 18.2% strains sensitive to H10 developed.At the start of treatment, 70.5% were H10 non-resistant; later on non-resistance was found in 77.3%. Non-resistance to low H concentrarion (1 mkg/ml) was 20.5% at the onset and 15.9% at follow-up test.CONCLUSION: A certain primary DR improvement has been observed. Issues of DR amplification require further study. ER -